Proterris
Boston
About Proterris
Proterris, a P2 clinical-stage firm, has pooled a dominant IP position in therapeutic uses of inhaled and small-molecule carbon monoxide. Proterris has prioritized CO development in delayed graft function (DGF), acute liver failure, and non-alcoholic steatohepatitis (NASH), with significant opportunities in a number of other indications, including but not limited to acute kidney injury (AKI), renal fibrosis, and idiopathic pulmonary fibrosis (IPF). It is headquartered in Boston, Massachusetts.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $2.0M
- Last round: Series Unknown (Jul 2019)
- Website: proterris.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/proterris-25775 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.